维生素A、E水平与孕期子痫前期病情轻重程度的相关性研究

目的探讨维生素A、E水平与孕期子痫前期病情轻重程度的相关性。方法回顾性分析2017年1月至2019年7月该院收治的154例子痫前期患者临床资料,将96例子痫前期患者纳入甲组,58例重度子痫前期患者纳入乙组,另取200例健康孕妇纳入丙组,分析维生素A、E与子痫前期病情轻重程度的相关性。结果乙组、甲组维生素A和维生素E水平低于丙组,差异有统计学意义(P0.05);维生素A水平与子痫前期病情轻重程度呈负相关(r0,P0.05),维生素E水平与子痫前期轻重程度呈负相关(r0,P0.05);子痫前期患者维生素A、E水平与低密度脂蛋白(LDL)、三酰甘油(TG)水平呈负相关(r0,P0.05),子痫前期患者维生素A、E水平与总胆固醇(TC)、高密度脂蛋白(HDL)水平呈正相关(r0,P0.05)。结论子痫前期患者维生素A、E水平较低,且维生素A、E水平降低可加重血脂代谢异常,引起子痫前期病情发展。     

子痫前期孕产妇血清补体相关因子与抗心磷脂抗体水平及其临床意义

[目的]探讨子痫前期孕产妇血清补体相关因子及抗心磷脂抗体水平及其临床意义.[方法]回顾性分析2016年12月至2018年3月于本院分娩66例子痫前期患者(轻度子痫前期组)和54例重度子痫前期患者(重度子痫前期组)的临床资料.选取同时期产检的正常产妇36例作为对照组.检测所有受试者血清中补体因子D(CFD)以及脂联素(A...     

早期预测子痫前期患者血清MicroRNAs标志物的筛选

目的:筛选早期子痫前期患者的血清MicroRNAs预测标志物。方法:选取2019年9月至2019年10月本院收治的5例子痫前期轻度患者以及5例子痫前期重度患者作为研究对象,划入研究组,分别为研究A组、研究B组,选取同期体检的5例正常孕妇作为对照组进行对比研究。在孕中、晚期实施动态监测,采用现代高通量测序技术检测血清中MicroRNAs表达,筛选高效早期预测标志物;并再按照以上标准各组选取50例研究对象,进行血液样本制作,采用实时定量PCR大样本验证标志物及靶基因表达。结果:研究A组、研究B组的两种RNA基因对比结果的百分比数值均明显高于对照组,P<0.05,差异具有统计学意义。子痫轻度以及重度患者的血清miR-210以及miR-520g在孕早期的表达水平明显高于对照组,结论可将血清miR-210以及miR-520g作为早期子痫前期患者良好的预测血清标志物,值得临床应用。     

游离脂肪酸与子痫前期和妊娠期糖尿病发生的相关性

目的:探讨孕晚期游离脂肪酸对子痫前期和(或)妊娠期糖尿病(GDM)发病率的影响。方法:选择417例孕晚期子痫前期和(或)GDM为观察组,另选2 018例正常妊娠孕妇为对照组。检测并比较2组血清总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)和游离脂肪酸(FFA)。采用logistic回归模型分析血脂子痫前期和(或)GDM的关系。结果:校正混杂因素[孕妇年龄、孕前体质指数(BMI)和采血时的孕周]后,孕晚期FFA浓度升高会增加子痫前期、GDM和子痫前期合并GDM的风险(P0.01)。孕晚期TG水平升高会增加子痫前期、GDM发生的风险(P0.001)。结论:孕晚期FFA水平升高可使子痫前期和(或)GDM发生风险增加。     

子痫前期患者血清微小RNAs的差异表达研究

目的探讨子痫前期患者血清微小RNAs(miRNAs)不同的表达水平,分析子痫前期相关标志物。方法选择10个子痫前期患者胎盘中差异表达的miRNA,分别收集该院30例子痫前期患者和30例正常妊娠孕妇孕早期(12~14周)、孕中期(20~24周)和孕晚期(28~32周)血清miRNAs,采用SYBR Green qRT-PCR法检测血清中10个miRNAs的表达量。结果子痫前期胎盘中高表达的3个miRNAs(miR-152、miR-183、miR-210)在子痫前期孕中、晚期血清中表达显著升高,而胎盘中高表达的miR-182仅在子痫前期孕晚期表达显著升高;子痫前期胎盘中低表达的6个miRNAs(miR-1、miR-328、miR-363、miR-377、miR-500、miR-584)在子痫前期各个孕期的表达,差异均无统计学意义(P0.05)。结论 miR-152、miR-183、miR-210在子痫前期孕中、晚期血清中表达显著升高,可能是预测子痫前期发生的良好生物标志物。     

预测急性心肌梗死患者转归的血清代谢物谱研究

目的采用液-质联用代谢组学研究平台寻找能在急性心肌梗死(AMI)患者入院时即预测患者转归的特异性代谢物。方法运用超高效液相色谱串联质谱(UPLC-MS/MS)代谢组学研究平台分析48例心绞痛患者、24例AMI好转者、24例AMI死亡者及48名体检健康者(正常对照组)代谢物数据,对代谢轮廓数据的变异性进行分析,构建疾病区分模型。采用受试者工作特征(ROC)曲线评估特征代谢物的临床诊断效能。结果成功构建了"正常对照组-心绞痛组-AMI好转组-AMI死亡组"的主成分分析(PCA)模型(R2X=40.2%,Q2=13.9%)及正交偏最小二乘判别分析(OPLS-DA)模型(R2X=79.0%,R2Y=83.2%,Q2=65.0%)。验证结果显示模型的预测准确度达100%。筛选并鉴定出10种可用于AMI预后判断的代谢物离子,其中4-羟基-6-二十二烷酮、N-乙酰-白三烯、溶血磷脂酰胆碱(LPC)[18:2(9Z,12Z)]、LPC(18:0)、LPC(P-16:0)、LPC[P-18:1(9Z)]、LPC[20:1(11Z)]、LPC[20:2(11Z,14Z)]在AMI死亡患者的血清中水平较低,L-苏氨酸、3-甲基-2-丁烯-1-硫醇水平较高,与AMI好转患者比较差异均有统计学意义(P0.05)。结论采用代谢组学分析方法找到的特征代谢物具有很好的预测AMI患者预后的能力,可作为潜在的疾病转归标志物进一步研究。     

胆石病患者胆汁酸代谢轮廓分析

目的探讨胆石病患者与健康人群血清胆汁酸谱差异,分析其对胆石病的辅助诊断价值及可能的成石机制。方法选取2018年1月至2019年1月到重庆医科大学附属第一医院就诊的胆石病患者(n=33)及健康志愿者(对照组,n=51)共84例为研究对象。采用超高效液相色谱-串联质谱分析法同时检测胆石病患者和健康志愿者血清中15种胆汁酸的水平,并对检测所得到的数据进行多个变量的分析,从而建立胆石病的临床诊断模型,筛选出合适的胆汁酸生物标志物,并对血清中的生物标志物的统计学意义及诊断价值进行分析。结果成功构建出胆石病的正交偏最小二乘法判别分析(OPLS-DA)模型。2组甘氨鹅脱氧胆酸、鹅脱氧胆酸、牛磺熊脱氧胆酸、甘氨胆酸、牛磺脱氧胆酸、牛磺石胆酸、牛磺鹅脱氧胆酸、牛磺胆酸水平比较,差异均有统计学意义(P<0.05)。结论胆汁酸代谢轮廓对临床诊断胆石病有较大的应用价值,有望用于胆石病的早期诊断及鉴别诊断。     

血清脂蛋白相关磷脂酶A2在子痫前期的应用价值研究

目的探讨血清脂蛋白相关磷脂酶A2(Lp-PLA2)在子痫前期中的应用价值。方法选择2014年1月至2016年1月在该院行剖宫产术终止妊娠的孕妇63例,其中正常妊娠组31例,子痫前期组32例,轻度子痫前期组15例,重度子痫前期组17例,收集患者的一般资料和血清指标,非条件Logistic逐步回归分析子痫前期的独立危险因素。结果子痫前期组总胆固醇(TC)、三酰甘油(TG)、极低密度脂蛋白胆固醇(VLDLC)、低密度脂蛋白胆固醇(LDL-C)、游离脂肪酸(FFA)和动脉硬化指数(AI)显著高于正常妊娠组,高密度脂蛋白胆固醇(HDL-C)显著低于正常妊娠组(P0.05);子痫前期组Lp-PLA2显著高于正常妊娠组(P0.05);Lp-PLA2和TC、TG、LDL-C呈正相关,和HDL-C呈负相关(P0.05);Lp-PLA2、TG和LDL-C是子痫前期的独立危险因素(P0.01),HDL-C是子痫前期的保护因素(P0.01)。结论子痫前期中存在脂质代谢紊乱,高Lp-PLA2水平可作为子痫前期预测的重要指标。     

全程护理干预对妊娠期高血压疾病病情进展的影响

目的：探讨全程护理干预对妊娠期高血压疾病的影响。方法：从我院就诊2400例孕妇中筛选出317例有可能发生妊娠期高血压疾病的孕妇,随即分为观察组160例,实施全程护理干预;对照组157例,给与常规指导。结果：观察组中发展为轻度子痫前期45．6％,重度子痫前期16．3％,子痫0．6％,无产妇死亡;对照组中发展为轻度子痫前期60．5％,重度子痫前期25．5％,子痫5．1％,产妇死亡2例,占1．3％。两组比较均有显著性差异（P〈0．01）。结论：对可能发生妊娠期高血压疾病的孕妇实施全程护理干预,是降低妊娠期高血压疾病发生发展的重要环节。     

水通道蛋白1和血管内皮生长因子在子痫前期胎盘中的表达与意义

目的:研究水通道蛋白1(AQP1)和血管内皮生长因子(VEGF)在子痫前期胎盘中的表达及关系。方法:应用免疫组织化学SP法分别检测20例正常足月妊娠、20例子痫前期轻度组、20例子痫前期重度组孕妇的胎盘、胎膜组织中AQP1和VEGF的表达。结果:免疫组化显示AQP1和VEGF在3组胎盘、胎膜中均有表达,AQP1在子痫前期组胎盘上的表达较正常妊娠组上调,VEGF在子痫前期组胎盘上的表达强度弱于正常妊娠组。胎盘中AQP1和VEGF的表达不呈相关性(P>0.05)。而羊膜上的AQP1和VEGF的表达强度呈相关性(P<0.05)。结论:胎盘上AQP1的表达上调与VEGF的表达下降,可能参与子痫前期的发生和发展。     

A high-throughput and untargeted lipidomics approach reveals new mechanistic insight and the effects of salvianolic acid B on the metabolic profiles in coronary heart disease rats using ultra-performance liquid chromatography with mass spectrometry

High-throughput lipidomics provides the possibility for the development of new therapeutic drugs. Accordingly, herein, we reveal the protective role of salvianolic acid B (Sal B) in rats with coronary heart disease (CHD) and propose a new mechanism for its action through a high-throughput and non-targeted lipidomics strategy. A CHD animal model was induced by consecutive high-fat diet feeding with vitamin D3 injection. At the end of the 8th week, the serum sample was analyzed to explore the metabolic biomarker and pathway changes using untargeted lipidomics based on ultra-performance liquid chromatography with mass spectrometry (UPLC/MS). In addition, blood and heart tissue samples were collected and processed for the detection of biochemical indicators and liver histological observation. After salvianolic acid B treatment, the levels of LDH, CK, CK-MB, MYO, CTn1, TG, TC, LDL-c, and Apo(b) were significantly lower than that in the model group, while the levels of HDL-c and Apo(a1) were significantly higher than that in the model group. Furthermore, the histological features of fibrosis and steatosis were also evidently relieved in the model group. A total of twenty-six potential biomarkers were identified to express the lipid metabolic turbulence in the CHD animal models, of which twenty-two were regulated by salvianolic acid B trending to the normal state, including TG(20:0/20:4/o-18:0), PC(20:4/18:1(9Z)), PC(18:3/20:2), PA(18:0/18:2), LysoPE(18:2/0:0), SM(d18:0/22:1), PE(22:6/0:0), LysoPE (20:4/0:0), sphinganine, Cer(d18:0/18:0), PS(14:0/14:1), PC (18:0/16:0), LysoPC(17:0), PE(22:2/20:1), PC(20:3/20:4), PE(20:4/P-16:0), PS(20:3/18:0), cholesterol sulfate, TG(15:0/22:6/18:1), prostaglandin E2, arachidonic acid and sphingosine-1-phosphate. According to the metabolite enrichment and pathway analyses, the pharmacological activity of salvianolic acid B on CHD is mainly involved in three vital metabolic pathways including glycerophospholipid metabolism, sphingolipid metabolism and arachidonic acid metabolism. Thus, based on the lipidomics-guided biochemical analysis of the lipid biomarkers and pathways, Sal B protects against CHD with good therapeutic effect by regulating glycerophospholipid metabolism, sphingolipid metabolism and arachidonic acid metabolism, inhibiting oxidative stress damage and lipid peroxidation.

High-throughput lipidomics provides the possibility for the development of new therapeutic drugs.     

Discovery and comparison of serum biomarkers for diabetes mellitus and metabolic syndrome based on UPLC-Q-TOF/MS

IntroductionDiabetes mellitus (DM) and metabolic syndrome (MetS) are systemic metabolic disorders, which have risk factors for diabetic cardiovascular and cerebral microvascular disease. It is very important to screen the metabolic biomarkers between DM and MetS patients, which can make patients benefit to a greater extent and prevent the occurrence of disease in advance.ObjectivesDiabetes mellitus (DM) and metabolic syndrome are a complex, chronic illness with a pronounced impact on the quality of life of many people. However, understanding the metabolic changes in patients and identifying high-risk individuals is crucial for prevention and disease management strategies.MethodsIn this study, a nontargeted metabolomics approach based on UPLC-Q-TOF/MS was used to find the differential metabolites in serum samples from patients with DM and MetS.ResultsMetabonomic analysis reveals metabolic differences between DM and HC with significant differences more than 60 metabolites. While, more than 65 metabolites have significant differences between MetS and HC. The independent disturbed pathway in the DM group was the FoxO signaling pathway. The independent disturbed pathways in the MetS group were the alpha-linolenic acid metabolism, glycerophospholipid metabolism and pyrimidine metabolism.The independent disturbed metabolites and the logistic regression result showed that betaine, alpha-linolenic acid, d-mannose, l-glutamine and methylmalonic acid can be used as a combinatorial biomarker to distinguish DM from healthy control. L-isoleucine, l-glutamine, PC(16:0/16:0), alpha-d-glucose, ketoisocaproic acid, d-mannose, uridine can be used as a combinatorial biomarker in MetS.ConclusionOur findings, on one hand, provide critical insight into the pathological mechanism of DM and MetS. On the other hand, supply a combinatorial biomarker to aid the diagnosis of diseases in clinical usage.     

Effect of cholestyramine on bile acid metabolism in normal man

The effect of cholestyramine administration on the enterohepatic circulation of bile acids was studied in eight normal volunteers. In six subjects the metabolism of sodium taurocholate-(14)C was determined after its intravenous injection before and during the 6th wk of cholestyramine administration, 16 g/day. In two subjects, the metabolism of cholic acid-(14)C was observed before and during the 2nd wk of cholestyramine, 16 g/day. Bile acid sequestration resulted in a more rapid disappearance of the injected primary bile acid and its metabolic products. The composition of fasting bile acids was promptly altered by cholestyramine to predominantly glycine-conjugated trihydroxy bile acid. In four subjects, unconjugated bile acid-(14)C was administered during cholestyramine administration; the relative proportion of glycine-conjugated bile acid-(14)C before enterohepatic circulation was similar to the relative proportion of unlabeled glycine-conjugated bile acid present in duodenal contents after an overnight fast, indicating that a hepatic mechanism was responsible for the elevated ratios of glycine- to taurine-conjugated bile acid (G: T ratios) observed. The relative proportions of both dihydroxy bile acids, chenodeoxycholic and deoxycholic, were significantly reduced. Steatorrhea did not occur, and the total bile acid pool size determined after an overnight fast was unaltered by cholestyramine. These findings suggest that in normal man bile acid sequestered from the enterohepatic circulation by cholestyramine is replaced by an increase in hepatic synthesis primarily via the pathway leading to production of glycocholic acid.     

子痫前期患者血清代谢物水平及其与疾病严重程度的相关性研究

目的 检测子痫前期患者血清中的代谢物水平,并探讨其与疾病严重程度的相关性及联合检测对重度子痫前期患者的诊断价值.方法 选取2019年5-12月在青岛大学附属医院就诊的子痫前期患者40例作为观察组,包括轻度子痫前期患者20例,重度子痫前期患者20例,同时另选取同期健康妊娠孕妇20例为对照组.采用基于液相色谱-串联质谱(L...     

不同时间段血乳酸水平对脓毒症院内死亡的预测价值比较：基于重症监护医学信息数据库

目的比较不同时间段的血乳酸水平对脓毒症院内死亡的预测价值,以期为临床上合理选用血乳酸提供一定的研究证据。 方法基于重症监护医学信息数据库,纳入3 299例脓毒症患者。根据患者院内死亡情况,将3 299例脓毒症患者分为院内存活组（2 445例）和院内死亡组（854例）。比较两组患者的性别比、监护室类型、简化急性生理学评分Ⅱ（SAPSⅡ）、序贯器官衰竭估计（SOFA）评分、入院24 h内血乳酸的最大值[血乳酸（24 h,max）]及最小值[血乳酸（24 h,min）]及24 ~ 48 h血乳酸的最大值[血乳酸（48 h,max）]及最小值[血乳酸（48 h,min）]。采用Logistic回归分析及受试者工作特征（ROC）曲线分析影响脓毒症患者院内死亡的相关因素,并用Z检验比较曲线下面积（AUC）。 结果院内存活组患者的血乳酸（24 h,max）[3.0（1.8,4.8）mmol/L vs. 3.6（2.1,6.3）mmol/L]、血乳酸（24 h,min）[1.5（1.1,2.2）mmol/L vs. 1.8（1.3,2.9）mmol/L]、血乳酸（48 h,max）[1.5（1.1,2.3）mmol/L vs. 2.5（1.5,4.4）mmol/L]、血乳酸（48 h,min）[1.3（1.0,1.8）mmol/L vs. 1.9（1.3,3.2）mmol/L]、SAPSⅡ评分[44（35,54）分vs. 48（37,59）分]及SOFA评分[6（4,9）分vs. 8（5,11）分]均较院内死亡组显著降低（H = 7.350、9.535、13.473、12.720、6.734、8.033,P均< 0.001）。将上述指标纳入Logistic回归分析,结果显示,血乳酸（24 h,max）[比值比（OR）= 1.099,95%置信区间（CI）（1.069,1.130）]、血乳酸（24 h,min）[OR = 1.300,95%CI（1.220,1.385）]、血乳酸（48 h,max）[OR = 1.330,95%CI（1.271,1.391）]、血乳酸（48 h,min）[OR = 1.558,95%CI（1.451,1.673）]、SAPSⅡ评分[OR = 1.014,95%CI（1.008,1.020）]和SOFA评分[OR = 1.084,95%CI（1.059,1.110）]均为影响脓毒症患者院内死亡的危险因素（P均< 0.001）。ROC曲线分析结果显示,血乳酸（24 h,max）[AUC = 0.574,95%CI（0.551,0.597）]、血乳酸（24 h,min）[AUC = 0.614,95%CI（0.591,0.636）]、血乳酸（48 h,max）[AUC = 0.693,95%CI（0.672,0.715）]、血乳酸（48 h,min）[AUC = 0.689,95%CI（0.668,0.710）]、SAPSⅡ评分[AUC = 0.577,95%CI（0.555,0.600）]及SOFA评分[AUC = 0.592,95%CI（0.569,0.614）]对脓毒症患者院内死亡均具有预测价值（P均< 0.001）,且血乳酸（48 h,max）和血乳酸（48 h,min）的AUC均显著高于血乳酸（24 h,max）（Z = 7.310、7.064,P均< 0.001）和血乳酸（24 h,min）（Z = 5.078、4.821,P均< 0.001）、SAPSⅡ评分（Z = 7.126、6.880,P均< 0.001）和SOFA评分（Z = 6.204、5.959,P均< 0.001）。 结论入院24 ~ 48 h的血乳酸水平对脓毒症患者院内死亡可能具有更好的预测价值。     

Inhibition of ileal bile acid transport by cyclosporin A in rat

Abstract. Chronic administration of cyclosporin A may induce cholestasis and this effect has been attributed to impaired hepatic bile salt synthesis, metabolism and transport. We investigated the effect of cyclosporin A on intestinal absorption of bile acids in the ileum of rat. Ileal bile acid absorption was measured by in vivo intestinal perfusion with cyclosporin A and the solvent Cremophor EL. During ileal perfusion with 25 μM glycocholic acid, the concentration of 2.8 mm cyclosporin A inhibited intestinal bile acid absorption on average by 34%. Additional experiments were performed with everted gut sacs of the distal ileum to evaluate active absorption. A dose and time dependent inhibition of the active intestinal absorption of bile acids was found, with a 50% transport inhibition at an average cyclosporin A concentration of 2.69mmolL^-'. Thus, cyclosporin A inhibits the active intestinal absorption of bile acids which may influence bile acid synthesis, turnover and secretion and may contribute to cyclosporin A induced cholestasis.     

血清类风湿因子对免疫比浊法测定甘胆酸的影响评估

目的评估类风湿因子对血清甘胆酸测定的影响并探讨结果审核办法。方法用含有高水平类风湿因子的血清分别稀释不同水平的甘胆酸血清样本,测定原始和不同稀释度的血清样本类风湿因子和甘胆酸水平,观察稀释后测定结果的变化曲线,确认干扰存在;同时平行检测抗核抗体,观察干扰情况。结果添加类风湿因子后的血清甘胆酸测定结果下降,与类风湿因子水平呈正相关,差异有统计学意义(P<0.05)。类风湿因子水平在545 IU/mL以下时对血清甘胆酸测定基本没有影响,随着水平升高,干扰强度上升,甘胆酸检测结果急剧下降;未观察到抗核抗体干扰甘胆酸的测定。结论血清样本中较高水平的类风湿因子会干扰甘胆酸的测定,导致血清甘胆酸水平假性降低,需要引起临床重视。结果审核时应结合血清丙氨酸氨基转移酶、天门冬氨酸氨基转移酶、总胆汁酸综合分析报告血清甘胆酸结果。     

Bile Acid Synthesis in Man: Metabolism of 7α-Hydroxycholesterol-14C and 26-Hydroxycholesterol-3H

The pathways of bile acid synthesis in man were evaluated by studying the metabolism of 7alpha-hydroxycholesterol-4-(14)C and 26-hydroxycholesterol-16, 22-(3)H administered parenterally to individuals requiring external biliary drainage. Techniques for the identification of metabolites were thin-layer chromatography, column chromatography, gas-liquid chromatography with stream splitting, and crystallization to constant specific activity. It was found that both compounds were rapidly metabolized to bile acids and excreted in bile. Of the total radioactivity recovered in bile as bile acids, 87% of the 26-hydroxycholesterol-(3)H and 90% of the 7alpha-hydroxycholesterol-(14)C was found to be metabolized to both chenodeoxycholate and cholate. Compared to 7alpha-hydroxycholesterol, a greater proportion of 26-hydroxycholesterol was found to be metabolized to chenodeoxycholate.These findings indicate that both 7alpha-hydroxycholesterol and 26-hydroxycholesterol can be intermediates in the metabolism of cholesterol to bile acids in man. The observation that conversion to cholate takes place less readily after C-26 hydroxylation is consistent with previous findings in other species.     

Essential fatty acids and the complications of diabetes mellitus

In animals and humans with diabetes mellitus there is evidence that normal metabolism of essential fatty acids is impaired. The main dietary essential fatty acids, linoleic acid of the n-6 series and alpha-linolenic acid of the n-3 series, must both be 6-desaturated and converted to further metabolites if they are to exert all their desirable effects on the body. 6-desaturation is impaired in diabetes and a lack of adequate rates of formation of the 6-desaturated metabolites may be involved in the abnormalities in membrane function, in lipid metabolism and in haemostasis and the microcirculatory system which are seen in diabetes. Attempts to overcome the block by giving very large amounts of dietary linoleic acid, or to by-pass the block by giving 6-desaturated metabolites such as gamma-linolenic acid and eicosapentaenoic acid, have both given promising results.     

Placental metabolic profiling in gestational diabetes mellitus: An important role of fatty acids

AimGestational diabetes mellitus (GDM) is the most common metabolic disorder during pregnancy. Accumulating studies have reported metabolites that are significantly associated with the development of GDM. However, studies on the metabolism of placenta, the most important organ of maternal‐fetal energy and material transport, are extremely rare. This study aimed to identify and discuss the relationship between differentially expressed metabolites (DEM) and clinical parameters of the mothers and newborns.MethodsIn this study, metabolites from 63 placenta tissues (32 GDM and 31 normal controls) were assayed by ultra‐performance liquid chromatography‐high resolution mass spectrometry (UPLC‐HRMS).ResultsA total of 1297 annotated metabolites were detected, of which 87 significantly different in GDM placenta. Lipids and lipid‐like molecules accounted for 62.1% of DEM as they were significantly enriched via the “biosynthesis of unsaturated fatty acids” and “fatty acid biosynthesis” pathways. Linoleic acid and α‐linolenic acid appeared to be good biomarkers for the prediction and diagnosis of GDM. In addition, the level of PC(14:0/18:0) was negatively correlated with neonatal weight. 14 metabolites significantly different in male and female offspring, with the most increase in female newborns.ConclusionEven if maternal blood glucose level is well controlled, there are still metabolic abnormalities in GDM. Lipids and lipid‐like molecules were the main differential metabolites, especially unsaturated fatty acids.